Venous Thromboembolism Complicated with COVID-19: What Do We Know So Far?
Acute Disease
Anticoagulants
/ therapeutic use
Betacoronavirus
/ pathogenicity
Biomarkers
/ blood
COVID-19
Coronavirus Infections
/ complications
Disseminated Intravascular Coagulation
/ complications
Fibrin Fibrinogen Degradation Products
/ metabolism
Heparin
/ therapeutic use
Humans
Intensive Care Units
Lung
/ blood supply
Pandemics
Pneumonia, Viral
/ complications
Pulmonary Embolism
/ complications
Respiratory Insufficiency
/ complications
Risk Factors
SARS-CoV-2
Survival Analysis
Troponin
/ blood
Venous Thromboembolism
/ complications
COVID-19
Deep vein thrombosis
Pulmonary emboli
Venous thromboembolism
Journal
Acta haematologica
ISSN: 1421-9662
Titre abrégé: Acta Haematol
Pays: Switzerland
ID NLM: 0141053
Informations de publication
Date de publication:
2020
2020
Historique:
received:
20
04
2020
accepted:
27
04
2020
pubmed:
13
5
2020
medline:
21
10
2020
entrez:
13
5
2020
Statut:
ppublish
Résumé
Coronavirus disease (COVID-19) is caused by the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and is responsible for the ongoing 2019-2020 pandemic. Venous thromboembolism (VTE), a frequent cardiovascular and/or respiratory complication among hospitalized patients, is one of the known sequelae of the illness. Hospitalized COVID-19 patients are often elderly, immobile, and show signs of coagulopathy. Therefore, it is reasonable to assume a high incidence of VTE among these patients. Presently, the incidence of VTE is estimated at around 25% of patients hospitalized in the intensive care unit for COVID-19 even under anticoagulant treatment at prophylactic doses. In this review, we discuss present knowledge of the topic, the unique challenges of diagnosis and treatment of VTE, as well as some of the potential mechanisms of increased risk for VTE during the illness. Understanding the true impact of VTE on patients with COVID-19 will potentially improve our ability to reach a timely diagnosis and initiate proper treatment, mitigating the risk for this susceptible population during a complicated disease.
Identifiants
pubmed: 32396903
pii: 000508233
doi: 10.1159/000508233
pmc: PMC7270063
doi:
Substances chimiques
Anticoagulants
0
Biomarkers
0
Fibrin Fibrinogen Degradation Products
0
Troponin
0
fibrin fragment D
0
Heparin
9005-49-6
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
417-424Informations de copyright
© 2020 S. Karger AG, Basel.
Références
Blood Adv. 2018 Nov 27;2(22):3226-3256
pubmed: 30482764
JAMA Cardiol. 2020 Jul 1;5(7):811-818
pubmed: 32219356
N Engl J Med. 2020 Apr 30;382(18):1708-1720
pubmed: 32109013
Eur Heart J. 2020 May 14;41(19):1858
pubmed: 32227120
Korean J Anesthesiol. 2014 Jul;67(1):61-5
pubmed: 25097742
Respirology. 2015 Jul;20(5):799-804
pubmed: 25728265
J Thromb Haemost. 2020 Jul;18(7):1752-1755
pubmed: 32267998
Acta Anaesthesiol Scand. 1991 Nov;35(8):741-4
pubmed: 1763593
J Travel Med. 2020 Mar 13;27(2):
pubmed: 32052846
J Thromb Thrombolysis. 2021 May;51(4):1107-1110
pubmed: 32246317
J Thromb Haemost. 2020 May;18(5):1094-1099
pubmed: 32220112
Ann Intern Med. 1998 Feb 1;128(3):243; author reply 244-5
pubmed: 9454537
N Engl J Med. 2020 Apr 2;382(14):1293-1295
pubmed: 32101660
Am J Manag Care. 2017 Dec;23(20 Suppl):S376-S382
pubmed: 29297660
J Thromb Haemost. 2020 Jun;18(6):1517-1519
pubmed: 32294295
J Thromb Thrombolysis. 2020 Oct;50(3):548-557
pubmed: 32524516
Chest. 2016 Feb;149(2):315-352
pubmed: 26867832
Lancet. 2020 Mar 28;395(10229):1054-1062
pubmed: 32171076
J Thromb Haemost. 2020 Jun;18(6):1421-1424
pubmed: 32271988
J Nucl Med. 2020 May;61(5):630-631
pubmed: 32238427
J Thromb Haemost. 2020 Apr;18(4):844-847
pubmed: 32073213
J Med Virol. 2020 Jul;92(7):791-796
pubmed: 32181911
Thromb Res. 2019 Sep;181:77-83
pubmed: 31376606
Am J Hematol. 2019 Jul;94(7):833-839
pubmed: 30945756
JAMA. 2018 Oct 16;320(15):1583-1594
pubmed: 30326130
J Thromb Haemost. 2020 May;18(5):1023-1026
pubmed: 32338827
J Am Coll Cardiol. 2020 May 12;75(18):2352-2371
pubmed: 32201335
Radiol Cardiothorac Imaging. 2020 Mar 16;2(2):e200067
pubmed: 33778561
JAMA Cardiol. 2020 Jul 1;5(7):802-810
pubmed: 32211816
BMJ. 2020 Mar 26;368:m1091
pubmed: 32217556
Blood. 2020 May 14;135(20):1788-1810
pubmed: 32092132
Thromb Res. 2020 Jul;191:145-147
pubmed: 32291094
Arterioscler Thromb Vasc Biol. 2014 Nov;34(11):2363-71
pubmed: 25304324
J Am Coll Cardiol. 2020 Jun 16;75(23):2950-2973
pubmed: 32311448
J Am Heart Assoc. 2020 Apr 7;9(7):e016219
pubmed: 32233755
J Intensive Care. 2020 Jul 10;8:49
pubmed: 32665858
JAMA Intern Med. 2020 Jul 1;180(7):934-943
pubmed: 32167524
Circulation. 2020 Jun 2;141(22):1739-1741
pubmed: 32271624
Int J Infect Dis. 2020 Feb;91:264-266
pubmed: 31953166
N Engl J Med. 2020 Apr 23;382(17):e38
pubmed: 32268022
Lancet. 2020 Feb 15;395(10223):507-513
pubmed: 32007143